Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon P Jones

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Antiviral Therapy|December 3, 2003
Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytesOmar Janneh, Patrick G Hoggard, John F Tjia, et al.
Molecular Pharmaceutics|February 5, 2011
Hydrophobically modified dendrons: developing structure-activity relationships for DNA binding and gene transfectionSimon P Jones, Nathan P Gabrielson, Chun-Ho Wong, et al.
Plos One|June 27, 2015
Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative DiseaseSimon P Jones, Nunzio F Franco, Bianca Varney, et al.
AIDS (London, England)|November 27, 2018
HIV brain latency as measured by CSF BcL11b relates to disrupted brain cellular energy in virally suppressed HIV infectionLucette A Cysique, Lauriane Jugé, Matthew J Lennon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2005
Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimensSimon P Jones, Nadeem Qazi, John Morelese, et al.
Brain Communications|December 31, 2019
Atomoxetine and citalopram alter brain network organization in Parkinson's diseaseRobin J Borchert, Timothy Rittman, Charlotte L Rae, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 11, 2016
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's DiseaseRobin J Borchert, Timothy Rittman, Luca Passamonti, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 4, 2016
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's DiseaseRobin J Borchert, Timothy Rittman, Luca Passamonti, et al.
Annals of Clinical and Translational Neurology|October 24, 2018
[<sup>18</sup>F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansionRichard W Bevan-Jones, Thomas E Cope, Simon P Jones, et al.
BMJ Open|July 29, 2025
Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and safety of oral atomoxetine for treating cognitive and behavioural changes in people with progressive supranuclear palsy syndromes in the UKRobert Durcan, Hugo Paula, Boyd C P Ghosh, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Antiviral Therapy|December 3, 2003
Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytesOmar Janneh, Patrick G Hoggard, John F Tjia, et al.
Molecular Pharmaceutics|February 5, 2011
Hydrophobically modified dendrons: developing structure-activity relationships for DNA binding and gene transfectionSimon P Jones, Nathan P Gabrielson, Chun-Ho Wong, et al.
Plos One|June 27, 2015
Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative DiseaseSimon P Jones, Nunzio F Franco, Bianca Varney, et al.
AIDS (London, England)|November 27, 2018
HIV brain latency as measured by CSF BcL11b relates to disrupted brain cellular energy in virally suppressed HIV infectionLucette A Cysique, Lauriane Jugé, Matthew J Lennon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2005
Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimensSimon P Jones, Nadeem Qazi, John Morelese, et al.
Brain Communications|December 31, 2019
Atomoxetine and citalopram alter brain network organization in Parkinson's diseaseRobin J Borchert, Timothy Rittman, Charlotte L Rae, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 11, 2016
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's DiseaseRobin J Borchert, Timothy Rittman, Luca Passamonti, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 4, 2016
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's DiseaseRobin J Borchert, Timothy Rittman, Luca Passamonti, et al.
Annals of Clinical and Translational Neurology|October 24, 2018
[<sup>18</sup>F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansionRichard W Bevan-Jones, Thomas E Cope, Simon P Jones, et al.
BMJ Open|July 29, 2025
Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and safety of oral atomoxetine for treating cognitive and behavioural changes in people with progressive supranuclear palsy syndromes in the UKRobert Durcan, Hugo Paula, Boyd C P Ghosh, et al.
Pageof 2